(VIANEWS) – Shares of BERGENBIO (Oslo Børs All-share Index_GI: BGBIO.OL) rose by a staggering 15.62% in 5 sessions from $6.53 to $7.55 at 19:27 EST on Monday, after four consecutive sessions in a row of gains. Oslo Børs All-share Index_GI is falling 0.89% to $1,365.78, after sequential sessions in a row of losses.
About BERGENBIO
BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of drugs to treat immune evasive, drug resistant, and metastatic cancers; and respiratory diseases. Its lead candidate is Bemcentinib, a bio-available small molecule AXL inhibitor, which is in Phase II clinical development in major cancer indications and COVID-19. Its Phase II clinical trial program focuses on treatment of non-small cell lung cancer, acute myeloid leukaemia, and myelodysplastic syndrome, as well as COVID-19. In addition, it is developing tilvestamab, an anti-AXL antibody that is in Phase Ib clinical trial. BerGenBio ASA has a collaboration agreement with Merck & Co. for clinical trials. The company was incorporated in 2007 and is based in Bergen, Norway.
Earnings Per Share
As for profitability, BERGENBIO has a trailing twelve months EPS of $-3.43.
Volume
Today’s last reported volume for BERGENBIO is 125449 which is 34.49% below its average volume of 191512.
More news about BERGENBIO (BGBIO.OL).
